Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis.
We tapered antiepileptic drugs in 40 patients with epilepsy due to neurocysticercosis who had been free of seizures for 2 years. All patients previously received a course of albendazole that resulted in complete destruction of brain cysts. We followed the patients prospectively from the time of diagnosis until 12 months after antiepileptic drug withdrawal. We evaluated the following prognostic factors for seizure recurrence: sex, number of seizures before control, type of seizures, number of parenchymal brain cysts before albendazole therapy, EEG findings, and CT findings after albendazole therapy. In the univariate analysis of prognostic factors for seizure recurrence, the development of brain calcifications caused by albendazole was the only factor associated with a significantly higher rate of relapse (p = 0.004). The multivariate analysis showed that patients who had both recurrent seizures and multiple brain cysts also had a higher risk of relapse than those with single seizures or single cysts (p = 0.05). This study suggests that the prognosis of epilepsy due to neurocysticercosis is not as benign as previously thought. Patients with residual calcifications and those with both recurrent seizures and multiple cysts before albendazole therapy have the highest rate of relapse after withdrawal of antiepileptic drugs.
Del Brutto
O H
OH
Department of Neurology, Luis Vernaza Hospital, Guayaquil, Ecuador.
D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage*; D001927:Brain Diseases / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002648:Child; D003551:Cysticercosis / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011859:Radiography; D012008:Recurrence
D015766:Albendazole